378185-91-2

Upstream product

• 378185-88-7 tert-butyl(4-iodo-3,5-dimethylphenoxy)dimethylsilane 
• 378185-89-8 4-(tert-butyldimethylsilanyloxy)-2,6-dimethylbenzaldehyde 
• 108-68-9 3,5-Dimethylphenol 
• 80826-86-4 4-iodo-3,5-dimethylphenol 
• 378185-90-1 (4-tert-Butyldimethylsilyloxy-2,6-dimethylphenyl)methanol 

Downstream Products

• 378185-97-8 (2R)-1-[(4R)-4-Benzyl-2-oxo-1,3-oxazolan-3-yl]-3-(4-tert-butyldimethylsilyloxy-2,6-dimethylphenyl)-2-phenylpropan-1-one 
• 378185-93-4 (2R)-1-[(4R)-4-Benzyl-2-oxo-1,3-oxazolan-3-yl]-2-cyclohexyl-3-(4-tert-butyldimethylsilyloxy-2,6-dimethylphenyl)propan-1-one 

Relevant academic research and scientific papers

Stereospecific syntheses of 2-alkyl and 2-phenyl substituted 3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acids

Stereospecific syntheses of 2-methyl-, 2-ethyl-, 2-cyclohexyland 2-phenyl- substituted 3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acids were developed. The key steps for the formation of the stereogenic centers involved the utilization of Evans' 4-benzyl-2-oxazolidinone chiral auxiliary. These compounds were designed to replace the N-terminal tyrosine residue in opioid peptides.